Net Income

After a strategic pivot to focus purely on cell and gene therapy, BioLife reports strong revenue growth and a profitable quarter, eyeing further gains in 2026.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

The AI semiconductor firm posts 37% annual revenue growth and a return to non-GAAP profit, proving its strategic pivot to intelligent edge devices is a success.

Structure Therapeutics reports strong Phase 2 data for its oral obesity pill, aleniglipron, positioning it as a key contender in the race for pill-based GLP-1s.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.

NuScale Power touts a 'breakthrough year' with landmark deals, but staggering financial losses and partner scrutiny test its path to commercialization.

The ad tech firm's stock surged on a strong Q4, but a full-year loss highlights its high-stakes pivot to AI and CTV to fuel future growth.

Clipper Realty's Q4 results show a stark divide in NYC real estate, as soaring apartment rents struggle to offset deep losses from its troubled office portfolio.

With TGA approval, Optellum's AI platform arrives to help tackle Australia's low lung cancer survival rates by enabling earlier, more accurate detection.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

Over 1,500 traders have given $6.1M to AI agents in a 21-day DeFi deathmatch where only one token survives. Is this the future or financial insanity?

With millions of Canadians suffering from dry eye, a new program combines advanced tech like IPL with personalized plans to offer hope and accessible relief.

The Puerto Rican banking giant's latest $0.75 dividend reflects strong financials and analyst confidence, solidifying its appeal for income-focused investors.

Viridien posts impressive 2025 profit growth and debt reduction, announcing a new CEO to navigate a selective, tech-focused deepwater exploration boom.

As Acorn preps its Q4 results, we look at the microcap's macro impact on grid reliability, cell towers, and the burgeoning smart energy market.

Long Beach's Farmers & Merchants Bank lands on Forbes' prestigious 'Best Banks' list, proving its community-first model is a formula for modern success.

ISI reports record profits, beating forecasts with a 9% revenue jump. Strategic investments in vertical integration and diversification fuel a major comeback.

A new report reveals a dramatic rise in employee concerns over toxic culture, safety, and AI, transforming ethics hotlines into strategic risk barometers.

A century-old Chicago food dynasty, Pastorelli Food Products, sees its iconic recipes and brand name hit the auction block in a $2.8M foreclosure sale.